Navigation Links
The MDS foundation supports vidaza's recommendation for European approval
Date:10/27/2008

The Myelodysplastic Syndromes (MDS) Foundation supports the positive opinion from the European Union's Committee for Medicinal Products for Human Use (CHMP) recommending approval of VIDAZA (azacitidine) for specific types of MDS patients, including those with high-risk MDS, chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).

The CHMP positive opinion was based upon data from the AZA-001 trial, which found that VIDAZA nearly doubled the two-year survival rate for higher-risk MDS patients compared to conventional care regimens (CCR) with a mean survival of 24.5 months compared to 15 months for patients who received CCR.

"We are very encouraged by the CHMP's recommendation for marketing approval for VIDAZA," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "The MDS Foundation is committed to making sure that patients in need are aware of and have access to new treatments, like VIDAZA, that can help patients to live longer and allow them to have a better quality of life."

The AZA-001 trial also showed that, VIDAZA delays the progression of MDS to acute myeloid leukemia (AML). Roughly 30 percent of patient diagnosed with MDS will progress to AML. The delay in progression is especially significant because patients with MDS are typically over the age of 65. According to the National Institute of Health, in this patient group, the average 5-year survival rate after diagnosis with AML is only approximately four percent.

MDS is a primary neoplasm of the bone marrow that is more prevalent than any of the leukemias. MDS affects the function of blood cells; red blood cells, white blood cells or platelets. The incidence of MDS is underestimated.


'/>"/>

Contact: Kathy Heptinstall
kheptinstall@MDS-Foundation.org
800-637-0839
The Myelodysplastic Syndromes Foundation
Source:Eurekalert

Page: 1

Related biology news :

1. Meyskens honored with AACR-Prevent Cancer Foundation award
2. Parkinsons Disease Foundation announces award of $150,000
3. The Camille & Henry Dreyfus Foundation to host important symposium on chemistry and the environment
4. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
5. National Science Foundation grant expands UMCES oyster research
6. Dunn Foundation gives Rice $3M for collaborative research grants
7. National Science Foundation grants Clemson professors award to develop nanoprobes
8. Entertainment Software Association Foundation awards grant to FAS for immune attack
9. A major prize in the chemical sciences announced by the Camille and Henry Dreyfus Foundation
10. UT Knoxville wins 2 $3M National Science Foundation research and education grants
11. The MDS Foundation supports the FDAs decision to expand vidaza label to include survival data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... Summary This report provides all the information ... partnering interests and activities since 2010. Download the ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/28/2017)...   Acuant , a leading provider of data ... to new and core technologies building upon the acquisition ... and desktop Acuant FRM TM facial recognition and ... time manual review of identity documents by accredited professionals. ... and most accurate capture software to streamline workflows by ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... TORONTO , March 29, 2017 /PRNewswire/ -  GeneNews Limited ... of BreastSentry™ , a new risk stratification test for ... reference lab, Innovative Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based ... five-year and lifetime risk for developing breast cancer.   ... BreastSentry measures ...
(Date:3/29/2017)... PUNE, India , March 29, 2017 ... Forecast to 2022 report is a specialized and comprehensive study on ... North America , Europe ... , Middle East and Africa ... Browse ...
(Date:3/28/2017)... ... March 28, 2017 , ... NetDimensions ... paper-based processes and enhance training plan management for consistent implementation of standards and ... with the SHL Group to help improve and streamline their training and employee ...
(Date:3/28/2017)... ... ... Franz Inc ., the leading supplier of Semantic Graph Database technology, today ... Bloor Research in its recent Graph Database Market Update report. ... it was rated as the easiest product to use.” – Bloor Research , ...
Breaking Biology Technology: